2020 ESTRO ACROP指南:胰腺癌靶区定义

2020-08-27 欧洲放射肿瘤学学会 Radiother Oncol . 2020 Aug 27;

2020年8月,欧洲放射肿瘤学学会(ESTRO)发布了胰腺癌靶区定义指南。尽管化疗和手术治疗在胰腺导管腺癌中占主导低危,放疗也在改变的多模式治疗中占有一定地位。本文主要针对胰腺癌放射治疗中靶区定义的相

中文标题:

2020 ESTRO ACROP指南:胰腺癌靶区定义

英文标题:

ESTRO ACROP guidelines for target volume definition in pancreatic cancer

发布机构:

欧洲放射肿瘤学学会

发布日期:

2020-08-27

简要介绍:

2020年8月,欧洲放射肿瘤学学会(ESTRO)发布了胰腺癌靶区定义指南。尽管化疗和手术治疗在胰腺导管腺癌中占主导低危,放疗也在改变的多模式治疗中占有一定地位。本文主要针对胰腺癌放射治疗中靶区定义的相关内容提供指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ESTRO-ACROP指南:胰腺癌靶区定义.pdf)] GetToolGuiderByIdResponse(projectId=1, id=65bbb1c001968153, title=2020 ESTRO ACROP指南:胰腺癌靶区定义, enTitle=ESTRO ACROP guidelines for target volume definition in pancreatic cancer, guiderFrom=Radiother Oncol . 2020 Aug 27;, authorId=0, author=, summary=2020年8月,欧洲放射肿瘤学学会(ESTRO)发布了胰腺癌靶区定义指南。尽管化疗和手术治疗在胰腺导管腺癌中占主导低危,放疗也在改变的多模式治疗中占有一定地位。本文主要针对胰腺癌放射治疗中靶区定义的相, cover=https://img.medsci.cn/2020910/1599671187096_2020535.jpg, journalId=0, articlesId=null, associationId=1624, associationName=欧洲放射肿瘤学学会, associationIntro=, copyright=0, guiderPublishedTime=Thu Aug 27 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月,欧洲放射肿瘤学学会(ESTRO)发布了胰腺癌靶区定义指南。尽管化疗和手术治疗在胰腺导管腺癌中占主导低危,放疗也在改变的多模式治疗中占有一定地位。本文主要针对胰腺癌放射治疗中靶区定义的相关内容提供指导。</p> </div> </div> </div>, tagList=[TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=718, guiderKeyword=胰腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3114, appHits=101, showAppHits=0, pcHits=773, showPcHits=3013, likes=1, shares=8, comments=4, approvalStatus=1, publishedTime=Thu Sep 10 01:37:10 CST 2020, publishedTimeString=2020-08-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Sep 10 01:06:35 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 13:09:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESTRO-ACROP指南:胰腺癌靶区定义.pdf)])
2020 ESTRO-ACROP指南:胰腺癌靶区定义.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1065333, encodeId=e8181065333a4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb545573242, createdName=ms4000000406966825, createdTime=Sat Oct 30 18:51:56 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919607, encodeId=ba4991960e9d, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:04:29 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915994, encodeId=dc0e915994e6, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efc13053194, createdName=1372a1226cm, createdTime=Tue Jan 12 19:03:23 CST 2021, time=2021-01-12, status=1, ipAttribution=)]
    2021-10-30 ms4000000406966825

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1065333, encodeId=e8181065333a4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb545573242, createdName=ms4000000406966825, createdTime=Sat Oct 30 18:51:56 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919607, encodeId=ba4991960e9d, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:04:29 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915994, encodeId=dc0e915994e6, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efc13053194, createdName=1372a1226cm, createdTime=Tue Jan 12 19:03:23 CST 2021, time=2021-01-12, status=1, ipAttribution=)]
    2021-01-25 ms4000001831181033

    好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1065333, encodeId=e8181065333a4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb545573242, createdName=ms4000000406966825, createdTime=Sat Oct 30 18:51:56 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919607, encodeId=ba4991960e9d, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:04:29 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915994, encodeId=dc0e915994e6, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efc13053194, createdName=1372a1226cm, createdTime=Tue Jan 12 19:03:23 CST 2021, time=2021-01-12, status=1, ipAttribution=)]
    2021-01-12 1372a1226cm

    好文章

    0

拓展阅读

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01